918643-51-3

Usage

Class

Imidazole derivative

Structure

Five-membered ring with two non-adjacent nitrogen atoms

Substituents

Ethyl group and iodine atom attached to the imidazole ring

Applications

Chemical and pharmaceutical industries

Usage

Building block for synthesis of other compounds, reagent in chemical reactions

Potential

Biological activity, interest in medicinal chemistry, drug development

Specific properties

Depend on interactions with other molecules and context of utilization

Upstream product

• 74-96-4 ethyl bromide 
• 71759-89-2 4-iodoimidazole 

Relevant academic research and scientific papers

PYRAZOLE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS

The present invention relates to compounds of formula (I) for their use in the treatment and/or prevention of auto-immune or auto-immune related diseases, cancer, viral infections, and central nervous system diseases and disorders, by inhibiting human deh

Synthesis of Complexes with Abnormal "protic" N-Heterocyclic Carbenes

Neutral 4-iodo-N-ethylimidazole 3 oxidatively adds to [Pt(PPh3)4] to give, in the presence of different tetraalkylammonium salts, complexes trans-[4], trans-[5], and trans-[6] containing an anionic C4-bound heterocycle with an unsubstituted ring-nitrogen atom. Complex trans-[4] reacts with the proton source NH4I under protonation of the ring-nitrogen atom to produce complex trans-[7]I which bears an NH,NR-substituted aNHC ligand. The reaction of trans-[4] with CH3I yields the complex trans-[8]I which has a classical aNHC ligand with two alkylated ring-nitrogen atoms.

Original 2-(3-Alkoxy-1 H -pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH)

Following our discovery of human dihydroorotate dehydrogenase (DHODH) inhibition by 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as well as 2-(4-benzyl-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-methylpyridine, we describe here the syntheses and evaluation of an array of azine-bearing analogues. As in our previous report, the structure-activity study of this series of human DHODH inhibitors was based on a phenotypic assay measuring measles virus replication. Among other inhibitors, this round of syntheses and biological evaluation iteration led to the highly active 5-cyclopropyl-2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-3-fluoropyridine. Inhibition of DHODH by this compound was confirmed in an array of in vitro assays, including enzymatic tests and cell-based assays for viral replication and cellular growth. This molecule was found to be more active than the known inhibitors of DHODH, brequinar and teriflunomide, thus opening perspectives for its use as a tool or for the design of an original series of immunosuppressive agent. Moreover, because other series of inhibitors of human DHODH have been found to also affect Plasmodium falciparum DHODH, all the compounds were assayed for their effect on P. falciparum growth. However, the modest in vitro inhibition solely observed for two compounds did not correlate with their inhibition of P. falciparum DHODH.

CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION

Compounds of formula (I) and pharmaceutical compositions thereof: wherein A1 A2 and A3 are each independently selected from the group consisting of N and CR3, wherein R1 is an optionally substituted heterocyclyl or an optionally substituted -(C1-6)alkyl-heterocyclyl, R2 is an optionally substituted aryl or an optionally subsisted heteroaryl, R4 is an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inbitor of HIV replication.